罗伟生教授治疗乙型肝炎后肝硬化验案举隅
A Case Study of Professor Luo Weisheng in the Treatment of Post-Hepatitis B Cirrhosis
DOI: 10.12677/tcm.2024.1311478, PDF,    科研立项经费支持
作者: 袁 鹰, 何源溢, 周 婧:广西中医药大学研究生院,广西 南宁;罗伟生*:广西中医药大学附属瑞康医院,国医堂名医馆,广西 南宁
关键词: 乙型肝炎后肝硬化中医肝脾同治软坚消癥化瘀法八珍荔核散结方Post-Hepatitis B Cirrhosis Traditional Chinese Medicine Liver and Spleen Being Treated Together Resolving Hard Lump and Removing Blood Stasis Bazhen Decoction Combined with Lychee-Nut Formula
摘要: 乙型肝炎后肝硬化是乙型肝炎逐步进展导致的慢性疾病。近年来,越来越多的研究表明,中医治疗乙肝肝硬化具有独特优势。罗伟生教授治疗乙肝肝硬化运用“肝脾同调”的治疗思路,在临床实践中,采用软坚消癥化瘀法,方选自拟方八珍荔核散结方加减治疗乙型肝炎后肝硬化,疗效可观,能够有效改善乙肝肝硬化患者的症状,降低肝功能指标,延缓病情进展。分享罗伟生教授治疗乙型肝炎后肝硬化(肝郁脾虚,气滞血瘀证)医案1则。
Abstract: Post-hepatitis B cirrhosis is a chronic disease caused by the progressive progression of hepatitis B. In recent years, more and more studies have shown that traditional Chinese medicine has unique advantages in the treatment of hepatitis B cirrhosis. Professor Luo Weisheng uses the therapeutic idea of “the same regulation of liver and spleen” in the treatment of hepatitis B cirrhosis. In clinical practice, he uses the method of resolving hard lump and removing blood stasis, and uses the Bazhen Decoction Combined with Lychee-Nut Formula for the treatment of hepatitis B cirrhosis. The curative effect is considerable, which can effectively improve the symptoms of patients with hepatitis B cirrhosis, reduce liver function indexes, and delay the progress of the disease. Professor Luo Weisheng’s medical case of treating post-hepatitis B cirrhosis (liver stagnation and spleen deficiency, qi stagnation and blood stasis syndrome) is shared.
文章引用:袁鹰, 何源溢, 周婧, 罗伟生. 罗伟生教授治疗乙型肝炎后肝硬化验案举隅[J]. 中医学, 2024, 13(11): 3219-3224. https://doi.org/10.12677/tcm.2024.1311478

参考文献

[1] Lian, J., Zeng, L.Y., Chen, J.Y., Jia, H.Y., Zhang, Y.M., Xiang, D.R., Yu, L., Hu, J.H., Lu, Y.F., Zheng, L., Li, L.J. and Yang, Y.D. (2013) De Novo Combined Lamivudine and Adefovir Dipivoxil Therapy vs Entecavir Monotherapy for Hepatitis B Virus-Related Decompensated Cirrhosis. World Journal of Gastroenterology, 19, 6278-6283. [Google Scholar] [CrossRef] [PubMed]
[2] 冯因克, 刘亚敏, 陈启龙. 慢性乙型肝炎后肝硬化中西医治疗研究进展[J]. 中国医药导报, 2016, 13(29): 28-31.
[3] 宋雪, 吕冠华, 范颖. 基于仲景“肝病实脾”理论探析现代临床肝病治法[J]. 亚太传统医药, 2024, 20(3): 194-198.
[4] Simillion, C., Semmo, N., Idle, J. and Beyoğlu, D. (2017) Robust Regression Analysis of GCMS Data Reveals Differential Rewiring of Metabolic Networks in Hepatitis B and C Patients. Metabolites, 7, Article 51. [Google Scholar] [CrossRef] [PubMed]
[5] 李毅, 刘艳, 寇小妮, 等. 乙肝后肝硬化症状学聚类研究[J]. 中医药导报, 2012, 18(2): 14-16.
[6] 李勇华. 乙型肝炎肝硬化腹水辨病论治探析[J]. 中国中医基础医学杂志, 2016, 22(3): 381-382.
[7] 李琼, 滕龙, 李永勤, 等. 周信有辨治病毒性肝硬化经验[J]. 中医杂志, 2018, 59(8): 643-645.
[8] 叶永安, 刘蕊洁, 杨先照, 等. 乙型肝炎肝硬化中医证型、证素分布特点文献研究[J]. 中医杂志, 2020, 61(4): 346-350.
[9] 李毅, 刘艳, 刘力, 等. 503例乙肝后肝硬化中医证候特征的因子分析[J]. 时珍国医国药, 2017, 28(5): 1149-1151.
[10] 刘光桥, 罗伟生. 罗伟生教授从虚论治慢性肝病验案举隅[J]. 中西医结合肝病杂志, 2021, 31(12): 1134-1135.
[11] 曾俊深, 杨靖芸, 甘雨晴, 等. 罗伟生教授运用八珍荔核方治疗肝癌临床经验[J]. 广西中医药, 2023, 46(6): 48-50.
[12] 杨靖芸, 曾俊深, 李众钦, 等. 罗伟生教授治疗乙型肝炎病毒感染相关肝病的经验[J]. 广西中医药大学学报, 2024, 27(1): 43-46, 52.
[13] 杨爽. 八珍荔核抗纤方联合恩替卡韦治疗肝郁脾虚夹瘀型慢性乙型肝炎临床疗效观察[D]: [硕士学位论文]. 南宁: 广西中医药大学, 2021.
[14] 甘雨晴, 谢家诚, 魏文悦, 等. 罗伟生以“化瘀四法”辨治慢性肝病[J]. 中医学报, 2024, 39(4): 782-786.
[15] 喻勤, 傅向阳, 罗伟生, 等. 荔枝核总黄酮对大鼠肝纤维化TGF-β/Smad信号通路的影响[J]. 中国实验方剂学杂志, 2013, 19(18): 223-227.
[16] 冯茵怡, 严炯艺, 夏星, 等. 荔枝核总黄酮对CCl4诱导的大鼠肝纤维化的影响及作用机制和潜在Q-marker的预测[J]. 中国中药杂志, 2020, 45(23): 5722-5731.
[17] 李俊利, 赵丹, 程留奇, 等. 富马酸丙酚替诺福韦对高病毒载量乙肝肝硬化代偿期患者抗病毒疗效、肝功能及肝纤维化血清学指标的影响分析[J]. 航空航天医学杂志, 2023, 34(10): 1222-1224, 1233.
[18] 李勇, 任立业, 徐鹤, 等. 香砂六君子汤加减联合恩替卡韦对乙肝肝硬化失代偿期患者的疗效及对T细胞亚群的影响[J]. 中国中西医结合消化杂志, 2024, 32(1): 35-41.